In general, we showed that HDAC inhibitor and PI3k inhibitor inhibit the migration, invasion, and proliferation of tamoxifen-resistant breast cancer cells and may be useful for the treatment of patients with breast cancer. The gene discussed is HDAC9; the disease is breast carcinoma.